Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
Xénia Gonda, Samata Sharma, Frank I. Tarazi
Expert Opinion on Drug Discovery (2018) Vol. 14, Iss. 1, pp. 81-89
Closed Access | Times Cited: 98

Showing 1-25 of 98 citing articles:

An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
Christopher M. Marshall, John G. Federice, Chloe N. Bell, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 14, pp. 11622-11655
Closed Access | Times Cited: 101
Major depressive disorder: Validated treatments and future challenges
Rabie Karrouri, Zakaria Hammani, Roukaya Benjelloun, et al.
World Journal of Clinical Cases (2021) Vol. 9, Iss. 31, pp. 9350-9367
Open Access | Times Cited: 101
Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
Roger S. McIntyre, Henrik Loft, Michael Cronquist Christensen
Neuropsychiatric Disease and Treatment (2021) Vol. Volume 17, pp. 575-585
Open Access | Times Cited: 59
The Implication of 5-HT Receptor Family Members in Aggression, Depression and Suicide: Similarity and Difference
Н. К. Попова, А. С. Цыбко, В. С. Науменко
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8814-8814
Open Access | Times Cited: 50
Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies
Omnia Kutkat, Yassmin Moatasim, Ahmed A. Al‐Karmalawy, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 48
Gut Microbiota Changes in Patients With Major Depressive Disorder Treated With Vortioxetine
Xiaolin Ye, Dong Wang, Huaqian Zhu, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 52
Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting
Michael Cronquist Christensen, Andrea Fagiolini, Ioana Florea, et al.
Journal of Affective Disorders (2021) Vol. 294, pp. 924-931
Open Access | Times Cited: 45
Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to SSRI Therapy
Roger S. McIntyre, Ioana Florea, Mads Møller Pedersen, et al.
The Journal of Clinical Psychiatry (2023) Vol. 84, Iss. 4
Open Access | Times Cited: 21
Depression in Major Neurodegenerative Diseases and Strokes: A Critical Review of Similarities and Differences among Neurological Disorders
Javier Pagonabarraga, Cecilio Álamo, Mar Castellanos, et al.
Brain Sciences (2023) Vol. 13, Iss. 2, pp. 318-318
Open Access | Times Cited: 20
Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study
Gregory W. Mattingly, Hongye Ren, Michael Cronquist Christensen, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 27
Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability
Michael Adair, Michael Cronquist Christensen, Ioana Florea, et al.
Journal of Affective Disorders (2023) Vol. 328, pp. 345-354
Open Access | Times Cited: 15
The effectiveness of vortioxetine on neurobiochemical metabolites and cognitive of major depressive disorders patients: A 8-week follow-up study
Yiliang Zhang, Shunkai Lai, Jianzhao Zhang, et al.
Journal of Affective Disorders (2024) Vol. 351, pp. 799-807
Closed Access | Times Cited: 4
Depression clinical trials worldwide: a systematic analysis of the ICTRP and comparison with ClinicalTrials.gov
Eugenia D. Namiot, Diana Smirnovová, Aleksandr V. Sokolov, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
The efficacy of vortioxetine in the acute treatment of major depressive disorder: A systematic review and meta-analysis
Isabella Berardelli, Elena Rogante, Federico Formica, et al.
Journal of Psychopharmacology (2025)
Closed Access
Chronic orofacial pain and pharmacological management – a Clinical guide
Guangzhao Guan, A Polonowita, Li Mei, et al.
Oral Surgery Oral Medicine Oral Pathology and Oral Radiology (2025)
Open Access
Efficacy of Vortioxetine Versus Escitalopram on the Cognitive Profile of Patients With Depressive Disorder: A Comparative Study
S Mishra, Varchasvi Mudgal, Koustubh R Bagul, et al.
Cureus (2025)
Open Access
Post-marketing safety evaluation of Vortioxetine: A decade-long pharmacovigilance study based on the FAERS database
Jianhong Wu, Na Li, Jun Gu, et al.
Journal of Affective Disorders (2025)
Closed Access
Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients
Anja Dvojkovic, Matea Nikolac Perković, Marina Šagud, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 105, pp. 110016-110016
Closed Access | Times Cited: 34
Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study
Michael Cronquist Christensen, Simon Nitschky Schmidt, Iría Grande
Journal of Psychopharmacology (2022) Vol. 36, Iss. 5, pp. 566-577
Open Access | Times Cited: 20
Clinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder
Michael Cronquist Christensen, Roger S. McIntyre, Michael Adair, et al.
CNS Spectrums (2023) Vol. 28, Iss. 6, pp. 693-701
Open Access | Times Cited: 12
Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis
Zejun Li, Shouhuan Liu, Qiuxia Wu, et al.
The International Journal of Neuropsychopharmacology (2023) Vol. 26, Iss. 6, pp. 373-384
Open Access | Times Cited: 12
Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies
Gregory W. Mattingly, Oscar Necking, Simon Nitschky Schmidt, et al.
Current Medical Research and Opinion (2023) Vol. 39, Iss. 4, pp. 613-619
Open Access | Times Cited: 11
Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism
Andrzej Pilc, Agata Machaczka, Paweł Kawalec, et al.
Expert Opinion on Drug Discovery (2022) Vol. 17, Iss. 10, pp. 1131-1146
Closed Access | Times Cited: 16
Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer’s disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea
Eduardo Cumbo, Michael Adair, Daniel Oudin Åström, et al.
Frontiers in Aging Neuroscience (2023) Vol. 14
Open Access | Times Cited: 9
Phytoconstituents Targeting the Serotonin 5-HT3 Receptor: Promising Therapeutic Strategies for Neurological Disorders
Likhit Akotkar, Urmila Aswar, Ankit Ganeshpurkar, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 6, pp. 1694-1710
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top